Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery

Abstract

Background Nanoscale drug-delivery systems (DDSs) have great promise in tumor diagnosis and treatment. Platelet membrane (PLTM) biomimetic DDSs are expected to enhance retention in vivo and escape uptake by macrophages, as well as minimizing immunogenicity, attributing to the CD47 protein in PLTM sends “ don’t eat me ” signals to macrophages. In addition, P-selectin is overexpressed on the PLTM, which would allow a PLTM-biomimetic DDS to specifically bind to the CD44 receptors upregulated on the surface of cancer cells. Results In this study, porous nanoparticles loaded with the anti-cancer drug bufalin (Bu) were prepared from a chitosan oligosaccharide (CS)-poly(lactic-co-glycolic acid) (PLGA) copolymer. These were subsequently coated with platelet membrane (PLTM) to form PLTM-CS-pPLGA/Bu NPs. The PLTM-CS-pPLGA/Bu NPs bear a particle size of ~ 192 nm, and present the same surface proteins as the PLTM. Confocal microscopy and flow cytometry results revealed a greater uptake of PLTM-CS-pPLGA/Bu NPs than uncoated CS-pPLGA/Bu NPs, as a result of the targeted binding of P-selectin on the surface of the PLTM to the CD44 receptors of H22 hepatoma cells. In vivo biodistribution studies in H22-tumor carrying mice revealed that the PLTM-CS-pPLGA NPs accumulated in the tumor, because of a combination of active targeting effect and the EPR effect. The PLTM-CS-pPLGA/Bu NPs led to more effective tumor growth inhibition over other bufalin formulations. Conclusions Platelet membrane biomimetic nanoparticles played a promising targeted treatment of cancer with low side effect. Electronic supplementary material The online version of this article (10.1186/s12951-019-0494-y) contains supplementary material, which is available to authorized users.

Platelet-Like Gold Nanostars for Cancer Therapy: The Ability to Treat Cancer and Evade Immune Reactions

“…We also showed that curcumin has additional therapeutic benefits by using R/P-cGNS for cancer therapies including photothermal effects, controlled drug release at elevated temperature, and the targeting of cancer cells through PLTs. Recently, many trials have been implemented to study the use of the tumor-targeting properties of PLTs (Dehaini et al, 2017;Wang et al, 2019). PLTs primarily play an important role in hemostasis; the initial stage of hemostasis begins with the binding of activated platelets to the damaged vessels exposing von Willebrand factor (vWF), which prevents excessive bleeding (Yun et al, 2016).…”

Erythrocyte Membrane Cloaked Curcumin-Loaded Nanoparticles for Enhanced Chemotherapy

“…The solution was sonicated until complete dissolution was achieved, and then added dropwise into 5 mL of deionized water under stirring at 1000 rpm. After leaving the suspension to stand for 3 h to evaporate the acetone [32], 500 μL of the resulting NP suspension was set aside for electron microscopy, dynamic light scattering (DLS) and zeta potential analysis, and the rest was stored at 4 °C for further use.…”

Cell-derived biomimetic nanoparticles as a novel drug delivery system for atherosclerosis: predecessors and perspectives

“…On the other hand, the platelet membrane is generally obtained by a repeated freeze–thaw process [ 104 ]. According to Zhang’s research, they obtained platelet membrane through freezing aliquots of platelet suspensions at −80°C before thawing them to room temperature.…”